Daily Management Review

FTSE 100 Demonstrates Poor Performance


04/28/2016


The sinking list of FTSE 100 casts different results on different firms.



FTSE 100 Demonstrates Poor Performance
Among other index, the FTSE 100 recently exhibited poor performances which were at the verge of sinking, while Standard Chartered was counted in with the “top performers” for the investors agreed on its “ongoing turnaround”.
 
Even though the company saw a fifty nine percent profit drop earlier this week, while “commodity prices, volatility in Chinese markets and weak emerging market sentiment” continued to be depressing, the investors were “pleased” to see a drop in “loan impairments”. In a comment the Head of Equity Research at Steve Clayton, Hargreaves Lansdown, said:
 “If the bank can hit the 10% return on equity target, and pay out half of earnings as a dividend, then an attractive yield may one day be possible, given the shares are trading far below book value. However, getting there will be easier said than done”.
 
Moreover, BP also did well in the latter half of the day after losing a “$485m” in the first quarter. As per the firm, the low prices of oil were cause of its bleak performance; although the Chief Executive at BP, Bob Dudley thinks:
"Market fundamentals continue to suggest that the combination of robust demand and weak supply growth will move global oil markets closer into balance by the end of the year”.
 
AstraZeneca faced a lot of “pressure” following its attempt of spreading “a double whammy of positive news”, for prior to the market’s opening, the company announced that “the US Food and Drug Administration had approved its Bevespi Aerosphere inhalation aerosol for treating patients with chronic obstructive pulmonary disease”. Digitallook explains:
“The product - glycopyrrolate and formoterol fumarate - is used for the long-term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema”.
 
However, later on AstraZeneca informed that Ironwood Pharmaceuticals were buying the U.S. Market Rights for “a newly-approved gout drug - Zurampic, or lesinurad”. The deal struck between both the companies enables Ironwood to “sell both Zurampic to treat high levels of uric acid in the blood of gout patients, and a fixed-dose combination of lesinurad and allopurinol”.
 
References:
http://www.digitallook.com/







Science & Technology

Toyota & Cartivator Are Building Flying Cars To Light Up The Olympic Flame Of 2020

Stock trading computers are not a future anymore

Temper Technology With Humanity - Apple's Cook Tells MIT Graduates

As Spying And Crime Tools Mix, Blame Game For Cyber Attacks Grows Murkier

Retailers Could Transform The Market Scenario Into Smart Shopping Experience For The Consumers With The Cloud

A Way To Unlock Wannacry Without Ransom Found By French Researchers

China to introduce face recognition payment system

Clues To Ransomware Worm's Lingering Risks Found By Security Experts

Nasdaq Brings ‘Analytics Hub’ To Provide Enhanced Trading Experience

Through XFi Launch, Comcast Moves Closer To Home Connectivity

World Politics

World & Politics

Trump to speak for America's dominance in the energy sector

U.S. Official Says Russians Targeted 21 Election Systems

The Britain’s Prime Minister To Bring Down Corporate Tax To Draw More Investments In The Country

Record 65.6 million people were displaced in 2016

Are millionaires preparing for an apocalypse?

EU says goodbye to mobile roaming charges

Denmark loses interest to electric cars

Global Airlines Conference Agenda To Accord Importance To Fresh Safety Concerns